X
NICE okays UCB’s Cimzia, nixes Almirall’s Ilumetri, in psoriasis
https://pharmaphorum.com/news/nice-okays-ucbs-cimzia-nixes-almirall-ilumetri-in-psoriasis/
psoriasis
J&J trumpets new data from Tremfya as psoriasis market braces for biosimilars
Humira biosimilars set to launch in EU next month
FDA approves UCB’s Cimzia in plaque psoriasis
The US FDA has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adults with moderate-to-severe plaque psoriasis
AbbVie to file long-acting psoriasis contender
AbbVie hopes risankizumab will rebuild sales after Humira patent expires
Bioelectronic wearable shows promise in psoriasis
Thync’s bioelectronic wearable significantly reduced symptoms in psoriasis patients within four weeks of use.
J&J’s psoriasis drug faces crowded market after US approval
J&J taking on next gen drugs from Novartis, Eli Lilly, and Valeant.
